A study to assess the safety and efficacy of nemolizumab (CD14152) in subjects with prurigo nodularis (PN) - Safety and Efficacy of Nemolizumab in P

GALDERMA R&D, SNC0 个研究点目标入组 100 人开始时间: 2017年7月26日最近更新: 2019年1月7日

适应症

试验速览

暂无简介。

•1. Male or female of at least 18 years at screening
•2. Clinical diagnosis of PN for at least 6 months with:
•- Prurigo lesions on upper limbs with or without lesions on the trunk or lower limbs
•- At least 20 nodules on the entire body with a bilateral distribution
•3. Severe pruritus defined as follows on a Numerical Rating Scale (NRS)
•- At the Screening visit 1: Mean of the worst daily intensity of the NRS score is = 7 over the previous 3 days
•- At the Baseline visit: Mean of the worst daily intensity of the NRS score is = 7 over the previous week;
•NOTE: NRS score should be measured on at least 5 days during the week preceding the baseline visit.
•4. Female subjects must fulfill one of the criteria below:
•- Female subjects of non-childbearing potential (postmenopausal [absence of menstrual bleeding for 1 year prior to screening, without any other medical reason], hysterectomy or bilateral oophorectomy);
•- Female subjects of childbearing potential who agree to a true abstinence (when in line with the preferred and usual lifestyle
•of the subject), or to use an effective method of contraception throughout the clinical trial and for 120 days after the last study drug administration
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 80
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 20

•1. Chronic pruritus resulting from another condition than PN such as scabies, insect bite, lichen simplex chronicus, psoriasis, acne, folliculitis, habitual picking, lymphomatoid papulosis, chronic actinic dermatitis, dermatitis herpetiformis, sporotrichosis, bullous disease
•2. Unilateral lesions of prurigo (e.g only one arm affected)
•3. Cutaneous bacterial or viral infection within 1 week before the baseline visit.
•4. Infection requiring treatment with oral or parenteral antibiotics, antivirals, antiparasitics or antifungals within 1 week before the screening visit, or during the screening period, unless completely resolved at the screening/ baseline visits respectively,
•5. Any uncontrolled or serious disease, or any medical or surgical condition, that may either interfere with the interpretation of the clinical trial results and/or put the subject at significant risk according to Investigator’s judgment (e.g. solid cancer, AIDS, serious or uncontrolled cardiac disease…) at Screening or Baseline.
•NOTE: Patients with controlled diseases such as diabetes mellitus, thyroid disorders and psychiatric disorders (such as depression and anxiety) are eligible
•6. Any active dermatoses that would need immediate therapy.

发起方

GALDERMA R&D, SNC